Go to Contents
Company History Targeting, Attacking, and Eradicating Cancers®

TOP

Company History

2020
2019
2018
2017
2016
2015
2014
2011
2008
2007
2020

2020

  • APR 2020

    Announced Interim clinical analysis of RCC (Renal Cell Carcinoma) in AACR (American Cancer Research Society) ; 16 Patients treated with Pexa-Vec (IV) and Cemiplimab - CR in 1 Patient, PR in 5 Patients, and 75% DCR

  • MAY 2020

    Construction of the COVID-19 candidate vaccines and small animal preclinical study

  • SEP 2020

    Neoadjuvant Study in Prostate Cancer, Multi-Center trials including Royal Melbourne Hospital in VIC, Australia ; Approved in HREC and plan to notify TGA

  • SEP 2020

    Pexa-Vec, FDA Orphan Drug Designation(ODD) to stage IIB-IV Melanoma

  • OCT 2020

    Pexa-Vec combined with PD-L1 monoclonal antibody clinical trial in metastatic Melanoma, partnership with LeesPharm ; Approved in China Regulatory Authority and expects recruitment

2019

2019

  • 2019.01

    Poster presentation on Phase 1 interim safety data of Pexa-Vec + Imfinzi clinical study at Gastrointestinal Cancers Symposium (GI ASCO)

2018

2018

  • 2018.12

    Poster presentation on safety data of the Phase 1 dose-escalation clinical trial of Pexa-Vec + Yervoy, at European Society for Medical Oncology (ESMO) Immuno-Oncology

  • 2018.11

    IND approved by Therapeutic Goods Administration on Phase 1 study of Pexa-Vec + Libtayo

  • 2018.06

    Poster presentation on Pexa-Vec as a neoadjuvant therapy at American Society of Clinical Oncology (ASCO)

    First patient enrollment in the US in the Phase 1 study of Pexa-Vec + Libtayo

  • 2018.04

    Presentation on pre-clinical data in Renal Cell Carcinoma (RCC) at American Association for Cancer Research Annual Meeting (AACR)

    Poster presentation on clinical data in Renal Cell Carcinoma (RCC) at International Oncolytic Virus Conference (IOVC)

  • 2018.03

    Stretched out additional vaccinia virus related patents in 13 European territories

  • 2018.02

    Approval by Ministry of Food and Drug Safety (MFDS) of South Korea to commence the Phase 1 clinical trial of Pexa-Vec + Libtayo in RCC

    Poster presentation on RCC clinical data at Genitourinary Cancers Symposium (GU ASCO)

  • 2018.01

    Expanded strategic manufacturing collaboration for JX-970

2017

2017

  • 2017.08

    Collaboration with National Cancer Institute of the US for developing Pexa-Vec in combination with immune checkpoint inhibitors

  • 2017.05

    Collaboration with Regeneron Pharmaceuticals for developing Pexa-Vec in combination with immune checkpoint inhibitors.

2015-2016

2016

  • 2016.12

    SillaJen was listed on KOSDAQ

2015

  • 2015.10

    SillaJen was selected by the government of South Korea as the major developer for the project of “Global State-of-the-art technology development for biomedical products"

2014

2014

  • 2014.03

    SillaJen acquired Jennerex, Inc., the global leader in oncolytic immunotherapeutics

    Jennerex was an early leader in the oncolytic virus field. Jennerex researchers showed that Pexa-Vec acted in three distinct ways to attack cancer : by infecting and killing cancer cells, by cutting off the blood supply totumors, and by activating the body’s own immune system to fight cancer

2011

2011

  • 2011.06

    Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer

2008

2008 - 2007

  • 2008.08

    Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007)

  • 2007.08

    Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001)